Immunomodulation for glioblastoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Opinion in Neurology

• Publication date

  2017-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/WCO.0000000000000451PMID 28368867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amendment history : Expression of Concern ( July 2019 ) Tandem CAR T cells targeting HER 2 and IL 13 R a 2 mitigate tumor antigen escape

  2019cited by this paper
• Therapeutic options in recurrent glioblastoma--An update.

  2016cited by this paper
• Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010.

  2016cited by this paper
• PD-L1 expression and prognostic impact in glioblastoma.

  2016cited by this paper
• The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities.

  2016cited by this paper
• Cancer Stem Cell‐Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion

  2016cited by this paper
• Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

  2016cited by this paper
• Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

  2015cited by this paper
• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• Chimeric antigen receptor T cells for cancer immunotherapy.

  2015cited by this paper
• Dendritic cell immunotherapy for brain tumors

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Structural and functional features of central nervous system lymphatics

  2015cited by this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cited by this paper
• CAR therapy: the CD19 paradigm.

  2015cited by this paper
• Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.

  2015cited by this paper
• Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch-repair deficiency

  2015cited by this paper
• Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

  2015cited by this paper
• Immunomodulation: checkpoint blockade etc.

  2015cited by this paper
• Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

  2015cited by this paper
• CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

  2015influential reference
• Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

  2015cited by this paper
• Vaccination strategies for neuro-oncology.

  2015cited by this paper
• Cancer and the Immune System: Basic Concepts and Targets for Intervention.

  2015cited by this paper
• Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes

  2014cited by this paper
• Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

  2014cited by this paper
• CNS macrophages and peripheral myeloid cells in brain tumours

  2014cited by this paper
• Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege

  2014cited by this paper
• Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

  2014cited by this paper
• Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

  2014cited by this paper
• Immune privilege of the CNS is not the consequence of limited antigen sampling

  2014cited by this paper
• Mechanisms of hypoxia-mediated immune escape in cancer.

  2014cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• The Etiology of Treatment-related Lymphopenia in Patients with Malignant Gliomas: Modeling Radiation Dose to Circulating Lymphocytes Explains Clinical Observations and Suggests Methods of Modifying the Impact of Radiation on Immune Cells

  2013cited by this paper
• Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages

  2013cited by this paper
• An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma

  2013cited by this paper
• VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.

  2013cited by this paper
• Efficiently stimulated adult microglia cross‐prime naive CD8+ T cells injected in the brain

  2013cited by this paper
• Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells

  2013cited by this paper
• The Controversial Role of Microglia in Malignant Gliomas

  2013cited by this paper
• EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

  2013cited by this paper
• T cells redirected to EphA2 for the immunotherapy of glioblastoma.

  2013cited by this paper
• Drainage of Cells and Soluble Antigen from the CNS to Regional Lymph Nodes

  2013cited by this paper
• Myeloid-derived suppressor cells in glioma

  2013cited by this paper
• Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

  2013influential reference
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells

  2012cited by this paper
• Capture, crawl, cross: the T cell code to breach the blood-brain barriers.

  2012cited by this paper
• Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors

  2012cited by this paper
• Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

  2012cited by this paper
• A restricted cell population propagates glioblastoma growth following chemotherapy

  2012cited by this paper
• IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival

  2012cited by this paper
• Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

  2012cited by this paper
• Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

  2012cited by this paper
• A restricted cell population propagates glioblastoma growth after chemotherapy

  2012cited by this paper
• Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain

  2011cited by this paper
• Hypoxia Potentiates Glioma-Mediated Immunosuppression

  2011cited by this paper
• Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

  2011cited by this paper
• Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

  2011cited by this paper
• Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide

  2011cited by this paper
• Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors.

  2011cited by this paper
• Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

  2011cited by this paper
• TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.

  2010cited by this paper
• Glioma cancer stem cells induce immunosuppressive macrophages/microglia.

  2010cited by this paper
• Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

  2010cited by this paper
• Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway

  2010cited by this paper
• Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors

  2010cited by this paper
• European Organization for Research and Treatment of Cancer

  2010cited by this paper
• Dynamics of central and peripheral immunomodulation in a murine glioma model

  2009cited by this paper
• Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis

  2009cited by this paper
• Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Neonatal and adult microglia cross‐present exogenous antigens

  2008cited by this paper
• Perivascular Spaces and the Two Steps to Neuroinflammation

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Selective Lymphopenia and Opportunistic Infections in Neuroendocrine Tumor Patients Receiving Temozolomide

  2007cited by this paper
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function

  2007cited by this paper
• What is the blood-brain barrier (not)?

  2007cited by this paper
• Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

  2006cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.

  2006cited by this paper
• Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain

  2006cited by this paper
• T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa

  2006cited by this paper
• Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

  2006cited by this paper
• Impaired capacity for upregulation of MHC class II in tumor‐associated microglia

  2005cited by this paper

• Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence.

  2025cites this paper
• Targeting myeloid cell polarization to prevent GBM recurrence.

  2025cites this paper
• The ClearPoint Array® frame: an MRI compatible system that supports non-craniotomy, multi-trajectory (NCMT) stereotactic procedures.

  2024cites this paper
• Mass Spectrometry Advances in Analysis of Glioblastoma

  2024cites this paper
• Influence of SLC40A1 on Cytokine Interactions and Immune Infiltration in Glioblastoma

  2024cites this paper
• Highly Active Myeloid Therapy for Cancer.

  2023cites this paper
• Kavain ablates the radio-resistance of IDH-wildtype glioblastoma by targeting LITAF/NF-κB pathway

  2022cites this paper
• Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma

  2021cites this paper
• The Presence and Potential Role of ALDH1A2 in the Glioblastoma Microenvironment

  2021cites this paper
• Complex Effectiveness of General Immunity in Modulating the Specific Immune Response in Gliomas

  2020cites this paper
• Personalized neoantigen vaccines: a glimmer of hope for glioblastoma

  2020cites this paper
• Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players

  2020cites this paper
• Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

  2019cites this paper
• Informed Consent for Neurosurgical Innovation

  2019cites this paper
• Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial

  2019cites this paper
• Content of cells of innate and acquired immunity in peripheral blood in brain tumors

  2019cites this paper
• Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma

  2018cites this paper
• T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection

  2018cites this paper
• Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach

  2018cites this paper
• The Induction of Immunogenic Cell Death ( ICD ) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma ( GBM )

  2018cites this paper
• New Directions in the Treatment of Glioblastoma

  2018cites this paper
• What are the prospects for combination therapy for glioblastoma?

  2017cites this paper
• Contemporary management of high-grade gliomas

  2017cites this paper
• From “One-Size-Fits-All” to a precision medicine approach in neurooncology and neurology practice

  2017cites this paper
• Neutrophils in Gliomas

  2017cites this paper
• Developmentally regulated signaling pathways in glioma invasion

  2017cites this paper
• Personalized Therapeutics and Pharmacogenomics: Integral to Personalized Health Care

  2017cites this paper